We open pre-market on 27 Feb 2026 with Intuitive Surgical, Inc. (ISRG) trading at $506.88 on the NASDAQ in the United States, driven by continued procedure growth and AI-enabled product momentum. ISRG stock shows volume 1,570,742 and a price-to-earnings ratio of 62.97 as investors weigh da Vinci 5 placements and Ion expansion. Today’s note connects recent analyst commentary, fresh institutional flows, and technicals to practical trade and portfolio questions for AI-focused investors.

ISRG stock: Pre-market snapshot and key stats

In pre-market trading Intuitive Surgical (ISRG) is at $506.88, up 0.71 from the prior close of $506.17, with a day range $501.40–$511.88 and market cap $180.01 billion. Volume sits at 1,570,742 versus an average of 1,865,776, 50-day average $536.63 and 200-day average $515.49, showing near-term consolidation below the 50-day. EPS is 8.05, PE 62.97, and the next earnings date is 21 Apr 2026, all important anchors for valuation and timing.

ISRG analysis: Fundamentals, margins and recurring revenue

Intuitive’s FY2024 results show recurring revenue at roughly 81% of sales and revenue growth near 18%–21% in recent quarters, driven by instruments, accessories and services. Key ratios include free cash flow per share 7.02, book value per share 50.55, and a current ratio of 4.87, which together signal strong cash generation and balance-sheet health. Analysts note margin pressure from tariffs and costs, but management guided 2026 growth to 13–15% and margin to 67–68%, which frames medium-term operating leverage expectations.

AI catalysts and product roadmap driving ISRG stock momentum

The da Vinci 5 rollout and AI-enabled features such as Case Insights and force-feedback instruments are cited as primary demand drivers for robotic adoption, with 427 system placements in the last reported quarter and over 11,100 installed systems globally. Ion diagnostic growth also accelerates optionality outside core soft-tissue surgery, with Ion procedures rising materially year-on-year. These product catalysts tie directly to procedure volumes, utilization and the recurring revenue stream that markets reward.

ISRG stock technicals and trading picture

Technicals show RSI 49.48, MACD histogram 4.24, ADX 35.40 (strong trend) and ATR 12.78, indicating measured volatility and recent trend strength but not overheating. Bollinger bands sit $474.21–$513.37, so current price trades near the upper band, and on-balance volume is negative, signaling uneven institutional flows. For traders, watch $474.21 as lower support and $603.88 as the 52-week high resistance level.

Meyka AI rates ISRG with a score out of 100 and forecast

Meyka AI rates ISRG with a score of 79.80 / 100 (Grade B+, Suggestion: BUY). This grade factors S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a yearly price of $602.22, implying an 18.82% upside from the current $506.88, and a monthly projection of $356.69 showing model sensitivity. Forecasts are model-based projections and not guarantees. For more details see our live ISRG page at Meyka ISRG page and analyst coverage at Zacks Research.

Risks, valuation and analyst context for ISRG stock

Valuation remains rich with price/sales 17.88 and price/book 10.09, while the consensus analyst price target averages near $616 and includes Buy-weighted coverage; MarketBeat notes a consensus target $615.86. Key risks are OUS budget constraints, tariff-related margin pressure, Medicaid policy shifts and competitive moves in China. Institutional ownership is high at roughly 83.6%, meaning sentiment can swing with large fund flows and earnings surprises.

Final Thoughts

ISRG stock opens pre-market on 27 Feb 2026 at $506.88 with AI-driven product upgrades and procedure growth providing the primary upside thesis. Fundamentals show strong recurring revenue, ample cash per share $16.72, and free cash flow per share $7.02, while valuation metrics (PE 62.97, P/S 17.88) demand continued revenue execution to justify multiples. Meyka AI’s model projects a $602.22 12‑month target, implying an 18.82% upside versus today’s price; investors should weigh that view against rich valuation and macro risks. We view Intuitive as a structural growth name in healthcare robotics for AI-focused portfolios, but recommend position sizing that reflects valuation and event risk. Our analysis aligns with consensus Buy-weighted coverage, and we will monitor the April earnings update and any regulatory or tariff developments that could change the outlook. Forecasts are model-based projections and not guarantees, and this note is informational only from Meyka AI’s AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.